Editing Orthostatic hypotension (section)

===Medications===
The medication [[midodrine]], an [[alpha-1 agonist|α<sub>1</sub>-adrenergic receptor agonist]], can benefit people with orthostatic hypotension,<ref name="Moya_2009"/><ref name=pmid25150287>{{cite journal | vauthors = Izcovich A, González Malla C, Manzotti M, Catalano HN, Guyatt G | title = Midodrine for orthostatic hypotension and recurrent reflex syncope: A systematic review | journal = Neurology | volume = 83 | issue = 13 | pages = 1170–1177 | date = September 2014 | pmid = 25150287 | doi = 10.1212/WNL.0000000000000815 | s2cid = 5439767 }}</ref> The main side effect is [[goose bumps|piloerection]] ("goose bumps").<ref name=pmid25150287/> [[Fludrocortisone]] is also used, although based on more limited evidence.<ref name="Moya_2009"/>

[[Droxidopa]], a [[norepinephrine]] [[prodrug]] and hence [[binding selectivity|non-selective]] [[adrenergic receptor agonist]], has been shown to be effective as well,<ref name="Mathias">{{cite journal | vauthors = Mathias CJ | title = L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the European experience | journal = Clinical Autonomic Research | volume = 18 | issue = Supplement 1 | pages = 25–29 | date = March 2008 | pmid = 18368304 | doi = 10.1007/s10286-007-1005-z | s2cid = 29861644 }}</ref> with few, mostly mild side effects reported.<ref>{{cite journal | vauthors = Kaufmann H, Freeman R, Biaggioni I, Low P, Pedder S, Hewitt LA, Mauney J, Feirtag M, Mathias CJ | display-authors = 6 | title = Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial | journal = Neurology | volume = 83 | issue = 4 | pages = 328–335 | date = July 2014 | pmid = 24944260 | pmc = 4115605 | doi = 10.1212/WNL.0000000000000615 }}</ref>

A number of other measures have slight evidence to support their use – [[indomethacin]], [[fluoxetine]], [[dopamine antagonist]]s, [[metoclopramide]], [[domperidone]], [[monoamine oxidase inhibitor]]s with [[tyramine]] (can produce severe [[hypertension]]), [[oxilofrine]], [[potassium chloride]], and [[yohimbine]].<ref name=pmid22591985>{{cite journal | vauthors = Logan IC, Witham MD | title = Efficacy of treatments for orthostatic hypotension: a systematic review | journal = Age and Ageing | volume = 41 | issue = 5 | pages = 587–594 | date = September 2012 | pmid = 22591985 | doi = 10.1093/ageing/afs061 | doi-access = free }}</ref>

[[Ampreloxetine]] (TD-9855), a [[norepinephrine reuptake inhibitor]], is in late-stage development for treatment of the condition.<ref name="AdisInsight-Ampreloxetine">{{cite web | title=Ampreloxetine - Theravance Biopharma | website=AdisInsight | date=21 November 2023 | url=https://adisinsight.springer.com/drugs/800026474 | access-date=26 September 2024}}</ref><ref name="HoxhajShahMuyolema2023">{{cite journal | vauthors = Hoxhaj P, Shah S, Muyolema Arce VE, Khan W, Sadeghzadegan A, Singh S, Collado GF, Goyal A, Khawaja I, Botlaguduru D, Razzaq W, Abdin ZU, Gupta I | title = Ampreloxetine Versus Droxidopa in Neurogenic Orthostatic Hypotension: A Comparative Review | journal = Cureus | volume = 15 | issue = 5 | pages = e38907 | date = May 2023 | pmid = 37303338 | pmc = 10257554 | doi = 10.7759/cureus.38907 | doi-access = free | url = }}</ref>